SCHEMBL14949028

SCHEMBL14949028

O=C(Nc1ccc(F)cc1)C1(C(=O)Nc2ccc(Oc3ncnc4cc5c(cc34)OCCOCCOCCO5)c(F)c2)CC1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 15/20 0.73
KDR P35968 12/20 0.67
AXL P30530 3/20 0.56
MERTK Q12866 2/20 0.53
PLK4 O00444 1/20 0.52
STK25 O00506 1/20 0.52
CIT O14578 1/20 0.52
AURKA O14965 1/20 0.52
CHUK O15111 1/20 0.52
MUSK O15146 1/20 0.52
EPHB6 O15197 1/20 0.52
MAPK13 O15264 1/20 0.52
MAP3K13 O43283 1/20 0.52
DAPK3 O43293 1/20 0.52
MAP3K7 O43318 1/20 0.52
RIPK2 O43353 1/20 0.52
JAK2 O60674 1/20 0.52
ROCK2 O75116 1/20 0.52
PAK3 O75914 1/20 0.52
CDKL5 O76039 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17447792 0.97 MET (0.67) METKDRAXLMERTKFLT3
SCHEMBL10133670 0.87 MET (0.71) METKDRAXLMERTKPLK4
SCHEMBL21218132 0.84 MET (0.75) METKDRAXLMERTKPLK4
SCHEMBL29693453 0.84 MET (1.00) METKDRAXLMERTKPLK4
SCHEMBL371651 0.84 MET (1.00) METKDRAXLMERTKPLK4
SCHEMBL17447780 0.84 MET (0.65) METKDRAXLMERTKPLK4
SCHEMBL29693555 0.82 MET (0.88) METKDRAXLMERTKAURKA
SCHEMBL4401230 0.82 MET (0.88) METKDRAXLMERTKAURKA
SCHEMBL29693551 0.82 MET (0.88) METKDRAXLMERTKAURKA
SCHEMBL4401193 0.82 MET (0.88) METKDRAXLMERTKAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242991-B2 Substituted fused heterocycles as c-Met tyrosine kinase inhibitors BETTA PHARMACEUTICALS CO., LTD (CN) 2016-01-26 US disclosed
US-20130123286-A1 Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors BETTA PHARMACEUTICALS CO., LTD. (CN) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123286-A1 Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors MET, RET, ABL1 MET 1/4885KDR 48/4885AXL 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.